Plasma von Willebrand Factor Levels Are an Independent Risk Factor for Adverse Events Including Mortality and Major Bleeding in Anticoagulated Atrial Fibrillation Patients
- 21 June 2011
- journal article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 57 (25), 2496-2504
- https://doi.org/10.1016/j.jacc.2010.12.033
Abstract
No abstract availableFunding Information
- Abbott Laboratories and Boston Scientific
- Abbott Laboratories and Boston Scientific
- Abbott Laboratories and Boston Scientific
This publication has 40 references indexed in Scilit:
- Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)European Heart Journal, 2010
- Usefulness of CHADS2 Score to Predict C-Reactive Protein, Left Atrial Blood Stasis, and Prognosis in Patients With Nonrheumatic Atrial FibrillationThe American Journal of Cardiology, 2010
- Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke RiskStroke, 2008
- Additive Role of Plasma von Willebrand Factor Levels to Clinical Factors for Risk Stratification of Patients With Atrial FibrillationStroke, 2006
- ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm SocietyJournal of the American College of Cardiology, 2006
- Combined Anticoagulant–Antiplatelet Use and Major Bleeding Events in Elderly Atrial Fibrillation PatientsStroke, 2004
- D-dimer can predict survival in patients with chronic atrial fibrillationBlood Coagulation & Fibrinolysis, 2004
- High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapyThrombosis and Haemostasis, 2003
- Plasma von Willebrand Factor and Soluble P-Selectin as Indices of Endothelial Damage and Platelet Activation in 1321 Patients With Nonvalvular Atrial FibrillationCirculation, 2002
- Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimatesThe American Journal of Cardiology, 1998